ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

relatlimab

Also written as “Relatlimab”, “Nivolumab + Relatlimab” and “relatlimab+nivolumab”.

Its studies are mostly in Melanoma · Carcinoma, Non-Small-Cell Lung · Neoplasms · Stomach Neoplasms · Carcinoma, Hepatocellular, led by Bristol-Myers Squibb.

Drug pageRelatlimab: every studyAll 50 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Mar 5, 202619 company-led studies, 5 open or runningNext primary completion: May 26, 2029 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibb195 open or runningphase 4since Mar 5, 2026Sep 25, 2013May 26, 2029phase 4 · NCT07459543

Also a collaborator on its studies: Exelixis, Novartis, Clovis Oncology, Johnson & Johnson, Halozyme Therapeutics and Ono Pharmaceutical.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Before these, 5 studies since Sep 25, 2013.

  1. Dec 15, 2016Phase 2 study in Advanced CancerNCT02996110 · 182 enrolled · United States, Australia, Austria and more
  2. Nov 6, 2017Phase 1 study in Advanced CancerNCT03335540 · 20 enrolled · United States
  3. Jun 9, 2018Named relatlimabINNProposed as its International Nonproprietary Name in WHO's List 119
  4. Oct 9, 2018Phase 2 study in Stomach NeoplasmsNCT03704077 · United States, Argentina, Australia and more
  5. Apr 1, 2019Phase 2 study in NeoplasmsNCT03899155 · 1,500 planned · United States, Argentina, Australia and more
  6. Jun 5, 2019Phase 1 study in MelanomaNCT03978611 · 11 enrolled · United States, Belgium, Canada and more
  7. Nov 5, 2020Phase 2 study in Carcinoma, Non-Small-Cell LungNCT04623775 · 468 enrolled · United States, Argentina, Australia and more
  8. Aug 4, 2021Phase 3 study in MelanomaNCT05002569 · 1,093 enrolled · United States, Argentina, Australia and more
  9. Feb 15, 2022Phase 2 study in Lymphoma, Non-HodgkinNCT05255601 · 5 enrolled · United States, Australia, France and more
  10. Apr 13, 2022Phase 2 study in Carcinoma, HepatocellularNCT05337137 · 82 enrolled · United States, Australia, Canada and more
  11. Aug 10, 2022Phase 1 study in Advanced Solid TumorsNCT05498480 · 6 enrolled · China
  12. Nov 15, 2022Phase 3 study in MelanomaNCT05625399 · 579 enrolled · United States, Australia, Austria and more
  13. Oct 20, 2023Phase 2 study in MelanomaNCT06101134 · 100 enrolled · United States, Chile, Greece and more
  14. Aug 16, 2024Phase 3 study in Carcinoma, Non-Small-Cell LungNCT06561386 · 1,000 planned · United States, Argentina, Australia and more
  15. Mar 5, 2026Phase 4 study in MelanomaNCT07459543 · 40 planned · India

Ahead

  1. May 26, 2029Primary completion: phase 4 study in MelanomaNCT07459543
  2. Aug 25, 2029Primary completion: phase 2 study in NeoplasmsNCT03899155
  3. Jul 30, 2030Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT06561386

TargetBeta

LAG3 →read by rule
“A monoclonal antibody directed against the inhibitor receptor lymphocyte activation gene-3 (LAG-3), ”NCIt, by rule
“Lymphocyte activation gene 3 protein inhibitor”ChEMBL 37, by rule

Other programs on LAG3

ProgramCompanyFurthest phaseStudies
fianlimabruleRegeneron Pharmaceuticalsphase 310
Anti-PD-1/LAG-3 Bispecific Antibody AK129ruleAkesophase 24
TQB2252Sino Biopharmaceuticalphase 11

Studies

All 19 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07459543Melanoma · India4Not yet recruitingMay 26, 202940
NCT06561386Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3RecruitingJul 30, 20301,000
NCT06101134Melanoma · United States, Chile, Greece and more2Active, not recruitingApr 10, 2025100
NCT05625399Melanoma · United States, Australia, Austria and more3Active, not recruitingAug 4, 2025579
NCT05498480Advanced Solid Tumors · China1CompletedJan 18, 20246
NCT05337137Carcinoma, Hepatocellular · United States, Australia, Canada and more2CompletedJul 5, 202582
NCT05255601Lymphoma, Non-Hodgkin · United States, Australia, France and more2TerminatedDec 3, 20255
NCT05002569Melanoma · United States, Argentina, Australia and more3TerminatedDec 16, 20241,093
NCT04623775Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more2CompletedJan 11, 2024468
NCT03978611Melanoma · United States, Belgium, Canada and more1TerminatedJul 26, 202311
NCT03899155Neoplasms · United States, Argentina, Australia and more2RecruitingAug 25, 20291,500
NCT03704077Stomach Neoplasms · United States, Argentina, Australia and more2WithdrawnFeb 27, 20220
NCT03335540Advanced Cancer · United States1CompletedMar 31, 202120
NCT02996110Advanced Cancer · United States, Australia, Austria and more2CompletedNov 23, 2021182
NCT02966548Neoplasms · Japan1CompletedJul 9, 202435
NCT02935634Advanced Gastric Cancer · United States, Australia, Canada and more2CompletedMay 11, 2022190
NCT02750514Advanced Cancer · United States, Australia, Austria and more2TerminatedJan 29, 2020295
NCT02061761Hematologic Neoplasms · United States, Canada2CompletedFeb 16, 2022106
NCT01968109Neoplasms by Site · United States, Australia, Austria and more2CompletedMay 22, 20241,482

How it is read

Names in the registry

  • “Relatlimab”, 13 entries
  • “Nivolumab + Relatlimab”, 3 entries
  • “relatlimab+nivolumab”, 1 entry
  • “relatlimab+nivolumab+rHuPH20”, 1 entry
  • “Nivolumab + Relatlimab Fixed Dose Combination”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.